Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.

Goff DA, Nicolau DP.

Clin Ther. 2013 Jun;35(6):766-71. doi: 10.1016/j.clinthera.2013.05.004.

PMID:
23795574
[PubMed - indexed for MEDLINE]
2.

Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.

Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.

Braz J Infect Dis. 2011 Sep-Oct;15(5):413-9.

PMID:
22230846
[PubMed - indexed for MEDLINE]
Free Article
3.

Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.

Kiratisin P, Keel RA, Nicolau DP.

Int J Antimicrob Agents. 2013 Jan;41(1):47-51. doi: 10.1016/j.ijantimicag.2012.09.007. Epub 2012 Nov 3.

PMID:
23127484
[PubMed - indexed for MEDLINE]
4.

Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.

Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2006 Nov;28(5):433-8.

PMID:
17046212
[PubMed - indexed for MEDLINE]
5.

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.

Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2011 Mar;37(3):225-9. doi: 10.1016/j.ijantimicag.2010.10.024. Epub 2010 Dec 18.

PMID:
21168997
[PubMed - indexed for MEDLINE]
6.
7.

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.

Koomanachai P, Bulik CC, Kuti JL, Nicolau DP.

Clin Ther. 2010 Apr;32(4):766-79. doi: 10.1016/j.clinthera.2010.04.003.

PMID:
20435246
[PubMed - indexed for MEDLINE]
8.

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.

Kotapati S, Kuti JL, Nicolau DP.

Surg Infect (Larchmt). 2005 Fall;6(3):297-304.

PMID:
16201939
[PubMed - indexed for MEDLINE]
9.
10.

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.

Kim A, Kuti JL, Nicolau DP.

Clin Ther. 2009 Nov;31(11):2765-78. doi: 10.1016/j.clinthera.2009.11.026.

PMID:
20110018
[PubMed - indexed for MEDLINE]
11.

Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.

Eagye KJ, Banevicius MA, Nicolau DP.

Crit Care Med. 2012 Apr;40(4):1329-32. doi: 10.1097/CCM.0b013e31823bc8d0.

PMID:
22425824
[PubMed - indexed for MEDLINE]
12.

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.

Ong CT, Kuti JL, Nicolau DP; OPTAMA Program.

Surg Infect (Larchmt). 2005 Winter;6(4):419-26.

PMID:
16433606
[PubMed - indexed for MEDLINE]
13.

Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.

Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.

J Clin Pharmacol. 2003 Oct;43(10):1116-23. Erratum in: J Clin Pharmacol. 2005 Mar;45(3):357.

PMID:
14517194
[PubMed - indexed for MEDLINE]
14.

Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.

Eagye KJ, Kuti JL, Nicolau DP.

Surg Infect (Larchmt). 2007 Apr;8(2):215-26.

PMID:
17437367
[PubMed - indexed for MEDLINE]
15.

Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals.

Keel RA, Kuti JL, Sahm DF, Nicolau DP.

Am J Health Syst Pharm. 2011 Sep 1;68(17):1619-25. doi: 10.2146/ajhp100569.

PMID:
21856807
[PubMed - indexed for MEDLINE]
16.

Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.

Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM.

Ann Pharmacother. 2014 Feb;48(2):178-86. doi: 10.1177/1060028013512474. Epub 2013 Nov 14.

PMID:
24259653
[PubMed - indexed for MEDLINE]
18.

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.

Diagn Microbiol Infect Dis. 2007 Feb;57(2):153-61. Epub 2006 Aug 23.

PMID:
16930925
[PubMed - indexed for MEDLINE]
19.

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

Moczygemba LR, Frei CR, Burgess DS.

Clin Ther. 2004 Nov;26(11):1800-7.

PMID:
15639692
[PubMed - indexed for MEDLINE]
20.

A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.

Eagye KJ, Nicolau DP, Lockhart SR, Quinn JP, Doern GV, Gallagher G, Abramson MA.

Ann Clin Microbiol Antimicrob. 2007 Oct 1;6:11.

PMID:
17908321
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk